risvutatug rezetecan

all catalysts(1)

News(6)

• GSK shares rise as $2.5B cost-cutting plan unveiled
  As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.
  biospace · 20d ago
• GSK partner Hansoh reports another phase 3 win for priority ADC
  Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.
  fiercebiotech · 20d ago
• GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
  Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…
  biospace · 25d ago
• GSK, Hansoh ADC extends survival in lung cancer study
  GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
  biopharma_dive · 1mo ago
• Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
  Plus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or Ris-Rez, met its primary end…
  endpoints · 1mo ago
• GSK boosts cancer pipeline with $11B Nuvalent buyout
  The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.
  biopharma_dive · 2mo ago